Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.68 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621395 | 0.90 | CYP2C9 (1.00) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL13791149 | 0.89 | CYP2C9 (0.65) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL3886246 | 0.88 | CYP2C9 (0.64) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL7208213 | 0.82 | LMNA (1.00) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL3880856 | 0.78 | CYP2C9 (0.69) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL28794517 | 0.77 | CYP2C9 (0.64) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL3880255 | 0.77 | ALDH1A1 (0.57) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL4129933 | 0.72 | CYP2C9 (0.58) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL27852359 | 0.70 | CYP2C9 (0.55) | CYP2C9CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL20016051 | 0.70 | GRIA2 (0.51) | CYP2C9CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP2C9 1909/4885CYP2C19 1280/4885LMNA 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.